BACKGROUND: @entity35343 phosphorylase (PyNPase) is identical to the protein, @entity1015 ( @entity1015 ), which has angiogenic activity. The physiological roles of PyNPase activity in the uterus and ovary are not known. In this study, we measured PyNPase activity in normal tissues of the uterus, ovary, and lymph nodes, and in benign and malignant lesions of these organs, and we considered the clinical implications of PyNPase activity in the uterus and ovary. METHODS: Tissue samples were obtained from 163 @entity1 (whose diseases are listed below) during surgery. PyNPase activity was measured spectrophotometrically, by monitoring the formation of @entity12244 . RESULTS: Mean PyNPase activity in tissues from the lesions of @entity1 with @entity5 (n = 20), uterine @entity1204 (n = 26), @entity2909 (n = 23), @entity43 (n = 46), @entity43 (n = 21), and @entity43 (n = 27) was significantly greater than that in the corresponding normal tissues. The PyNPase activity in the normal endometrium was significantly higher in the secretory phase than in the proliferative phase. The activity in normal or metastatic lymph nodes was significantly greater than that in normal tissues of the uterus and ovary. Mean PyNPase activity in cancerous cervical tissues was significantly greater than that in cancerous endometrial tissues or cancerous ovarian tissues. There were no significant differences in PyNPase activity in @entity5 , @entity43 tissues according to @entity5 stage. The enzyme activity appeared to be greater in histopathological G3 grade @entity1204 than in G1 and G2 @entity1204 . The enzyme activity in mucinous @entity420 was significantly lower than that in serous, endometrioid, and @entity16488 . All @entity1 with cervical @entity957 with PyNPase activity greater than 500 nmol/min per mg protein exhibited lymph node @entity3 . CONCLUSION: Increased PyNPase activity consistently reflected @entity5 , and varying levels of activity were seen in different histologic cell types. This enzyme activity may be involved in cervical @entity957 , in normal and metastatic lymph nodes, and in the normal, secretory phase in the endometrium.

XXXX phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian endometriosis', 'ovarian cancer', 'endometrial cancer, and ovarian cancer', 'benign epithelial ovarian tumor'] @entity12244 :: ('MESH:C001943', 'Chemical') :: ['5-fluorouridine'] @entity16488 :: ('MESH:D018262', 'Disease') :: ['clear cell adenocarcinomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer', 'neoplastic growth'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas'] @entity1015 :: ('1890', 'Gene') :: ['PD-ECGF', 'platelet-derived endothelial cell growth factor'] @entity35343 :: ('CHEBI:26440', 'Chemical') :: ['Pyrimidine nucleoside'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of the ovary'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity2909 :: ('MESH:D007889', 'Disease') :: ['leiomyoma']
@entity35343 :: (CHEBI:26440,Chemical) :: ['Pyrimidine nucleoside']
